Israel’s Teva has reported positive results of the Phase III trial of its Olanzapine LAI schizophrenia treatment that it has been developing with France’s Medincell. The once-a-month injections met all endpoints. It is likely to be an effective remedy without any serious side effects.
Another schizophrenia treatment
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.